{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:21:46Z","timestamp":1791397306976,"version":"4.3.3"},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T00:00:00Z","timestamp":1386806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.ymgme.2013.11.015","type":"journal-article","created":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T15:16:14Z","timestamp":1386774974000},"page":"63-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"title":["Early initiation of enzyme replacement therapy for the mucopolysaccharidoses"],"prefix":"10.1016","volume":"111","author":[{"given":"Joseph","family":"Muenzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2013.11.015_bb0005","first-page":"3421","article-title":"The mucopolysaccharidoses","volume":"vol. III","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.pediatrneurol.2004.10.009","article-title":"Mucopolysaccharidosis type II in females: case report and review of literature","volume":"32","author":"Tuschl","year":"2005","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1172-5-14","article-title":"Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review","volume":"5","author":"Pinto","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0025","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5years: results of a multinational study of recombinant human alpha-l-iduronidase (laronidase)","volume":"120","author":"Wraith","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"Harmatz","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0040","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","article-title":"Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"94","author":"Harmatz","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10545-009-9007-8","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase","volume":"33","author":"Harmatz","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/GIM.0b013e318206786f","article-title":"Idursulfase treatment of Hunter syndrome in children younger than 6years: results from the Hunter Outcome Survey","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0060","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0065","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00431-011-1606-3","article-title":"The role of enzyme replacement therapy in severe Hunter syndrome\u2014an expert panel consensus","volume":"171","author":"Muenzer","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0070","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1517\/14712598.8.7.1003","article-title":"Laronidase (Aldurazyme): enzyme replacement therapy for mucopolysaccharidosis type I","volume":"8","author":"Pastores","year":"2008","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucopolysaccharidosis I: management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0080","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1750-1172-6-55","article-title":"Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"6","author":"de Ru","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jpeds.2008.07.004","article-title":"Use of enzyme replacement therapy (laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients","volume":"154","author":"Wynn","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0090","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.bmt.1705934","article-title":"Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome","volume":"41","author":"Tolar","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0095","first-page":"743","article-title":"Alpha-l-iduronidase therapy for mucopolysaccharidosis type I","volume":"2","author":"Tolar","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jpeds.2012.07.052","article-title":"Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome","volume":"162","author":"Eisengart","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0105","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0110","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2174\/138920111795542651","article-title":"Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies","volume":"12","author":"de Ruijter","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0115","article-title":"A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4-7.5years) with Hunter syndrome receiving idursulfase enzyme replacement therapy","author":"Giugliani","year":"2013","journal-title":"Genet Med."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0120","unstructured":"Aldurazyme (laronidase) solution for intravenous infusion [prescribing information]. BioMarin Pharmaceutical Inc., Novato, CA and Genzyme Corporation, Cambridge, MA; 2011."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0125","series-title":"Elaprase\u00ae (idursulfase) Solution for Intravenous Infusion [Prescribing Information]","year":"2013"},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2013.11.015_bb0130","first-page":"S100","article-title":"Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders","volume":"47","author":"Miebach","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0135","series-title":"Naglazyme (Galsulfase) Injection for Intravenous Use [Prescribing Information]","year":"2011"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0140","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.amjcard.2006.02.047","article-title":"Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I","volume":"98","author":"Braunlin","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","article-title":"A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6years","volume":"90","author":"Sifuentes","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0150","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/S1047951109003576","article-title":"The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses","volume":"19","author":"Fesslova","year":"2009","journal-title":"Cardiol. Young"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0155","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2013.11.015_bb0160","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9444-z","article-title":"Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I","volume":"36","author":"Brands","year":"2013","journal-title":"II and VI. J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2013.11.015_bb0165","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10545-012-9481-2","article-title":"Enzymereplacement therapy for mucopolysaccharidosis VI: long-term cardiac effects ofgalsulfase (Naglazyme\u00ae) therapy","volume":"36","author":"Braunlin","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0170","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10545-011-9317-5","article-title":"Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy","volume":"34","author":"Manara","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10545-010-9059-9","article-title":"Efficacy of recombinant human alpha-l-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients","volume":"33","author":"Tylki-Szymanska","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0180","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1164\/ajrccm\/144.5.1202","article-title":"Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society","volume":"144","year":"1991","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0185","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1164\/rccm.200708-1248OC","article-title":"Reference ranges for spirometry across all ages: a new approach","volume":"177","author":"Stanojevic","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"8","key":"10.1016\/j.ymgme.2013.11.015_bb0190","doi-asserted-by":"crossref","first-page":"737-44","DOI":"10.1111\/j.1460-9592.2012.03825.x","article-title":"A retrospectiveaudit of anesthetic techniques and complications in children withmucopolysaccharidoses","volume":"22","author":"Frawley","year":"2012","journal-title":"Paediatr Anaesth"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0195","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1126\/science.169.3941.141","article-title":"Inborn errors of mucopolysaccharide metabolism","volume":"169","author":"Neufeld","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0200","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10545-008-1040-5","article-title":"Pathogenic cascades in lysosomal disease\u2014why so complex?","volume":"32","author":"Walkley","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. 5","key":"10.1016\/j.ymgme.2013.11.015_bb0205","doi-asserted-by":"crossref","first-page":"v13","DOI":"10.1093\/rheumatology\/ker395","article-title":"Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: glycosaminoglycan storage is merely the instigator","volume":"50","author":"Clarke","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2353\/ajpath.2008.070564","article-title":"Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases","volume":"172","author":"Simonaro","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0215","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.cellbio.22.010605.093433","article-title":"The molecular diversity of glycosaminoglycans shapes animal development","volume":"22","author":"Bulow","year":"2006","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1096\/fj.05-4682rev","article-title":"Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation","volume":"20","author":"Taylor","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0225","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1017\/S1462399408000550","article-title":"The mucopolysaccharidoses: a success of molecular medicine","volume":"10","author":"Clarke","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0230","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/nature05817","article-title":"Heparan sulphate proteoglycans fine-tune mammalian physiology","volume":"446","author":"Bishop","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0235","doi-asserted-by":"crossref","first-page":"C1387","DOI":"10.1152\/ajpcell.00346.2007","article-title":"Endogenous heparan sulfate and heparin modulate bone morphogenetic protein-4 signaling and activity","volume":"294","author":"Khan","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0240","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.mrgentox.2011.02.005","article-title":"DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; protective effect of enzyme replacement therapy","volume":"721","author":"Filippon","year":"2011","journal-title":"Mutat. Res."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0245","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cca.2007.09.008","article-title":"Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy","volume":"387","author":"Pereira","year":"2008","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0250","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1111\/j.1600-0854.2009.00987.x","article-title":"Glycosaminoglycan chains affect exocytic and endocytic protein traffic","volume":"10","author":"Kobialka","year":"2009","journal-title":"Traffic"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0255","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4161\/auto.5.2.7390","article-title":"Self-eating in skeletal development: implications for lysosomal storage disorders","volume":"5","author":"Settembre","year":"2009","journal-title":"Autophagy"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0260","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/jcp.22039","article-title":"Evidence of lysosomal membrane permeabilization in mucopolysaccharidosis type I: rupture of calcium and proton homeostasis","volume":"223","author":"Pereira","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0265","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1074\/jbc.M110.192062","article-title":"Secondary storage of dermatan sulfate in Sanfilippo disease","volume":"286","author":"Lamanna","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0270","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.semcdb.2004.03.002","article-title":"Secondary accumulation of gangliosides in lysosomal storage disorders","volume":"15","author":"Walkley","year":"2004","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0275","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bbamcr.2008.11.014","article-title":"Secondary lipid accumulation in lysosomal disease","volume":"1793","author":"Walkley","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0280","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1042\/BST0381442","article-title":"Storage problems in lysosomal diseases","volume":"38","author":"Heard","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0285","first-page":"218","article-title":"Localization and pattern of expression of extracellular matrix components in human heart valves","volume":"14","author":"Latif","year":"2005","journal-title":"J. Heart Valve Dis."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0290","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0002-9149(76)90468-9","article-title":"The heart in the Hurler syndrome: gross, histologic and ultrastructural observations in five necropsy cases","volume":"38","author":"Renteria","year":"1976","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0295","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-3476(00)70117-X","article-title":"Sudden death in Hunter syndrome caused by complete atrioventricular block","volume":"136","author":"Hishitani","year":"2000","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0300","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.carpath.2010.06.004","article-title":"Clear cells in the atrioventricular valves of infants with severe human mucopolysaccharidosis (Hurler syndrome) are activated valvular interstitial cells","volume":"20","author":"Braunlin","year":"2011","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0305","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.2353\/ajpath.2007.070251","article-title":"The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology","volume":"171","author":"Liu","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0310","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/eurheartj\/ehi248","article-title":"Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors","volume":"26","author":"Fondard","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0315","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s10545-005-0211-x","article-title":"Mucopolysaccharidosis I under enzyme replacement therapy with laronidase\u2014a mortality case with autopsy report","volume":"28","author":"Lin","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.ymgme.2013.11.015_bb0320","first-page":"S53-7","article-title":"Postmortem studies on a patient withmucopolysaccharidosis type I: histopathological findings after one year of enzymereplacement therapy","volume":"32","author":"Yano","year":"2009","journal-title":"J Inherit Metab Dis."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0325","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s002239900656","article-title":"Histomorphometric analysis of the tibial growth plate in a feline model of mucopolysaccharidosis type VI","volume":"65","author":"Nuttall","year":"1999","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0330","first-page":"1542","article-title":"Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options","volume":"2011","author":"Oussoren","year":"1812","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0335","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1399-0004.1998.tb02745.x","article-title":"Murine MPS I: insights into the pathogenesis of Hurler syndrome","volume":"53","author":"Russell","year":"1998","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0340","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/PRM-2010-0120","article-title":"Cartilage and chondrocyte pathology in the mucopolysaccharidoses: the role of glycosaminoglycan-mediated inflammation","volume":"3","author":"Simonaro","year":"2010","journal-title":"J. Pediatr. Rehabil. Med."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0345","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/labinvest.3780345","article-title":"Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses","volume":"81","author":"Simonaro","year":"2001","journal-title":"Lab. Invest."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0350","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1073\/pnas.0912937107","article-title":"Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses","volume":"107","author":"Simonaro","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0355","doi-asserted-by":"crossref","first-page":"e22447","DOI":"10.1371\/journal.pone.0022447","article-title":"Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI","volume":"6","author":"Eliyahu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0360","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/prrv.2001.0173","article-title":"Skeletal dysplasias and their effect on the respiratory system","volume":"2","author":"Mogayzel","year":"2001","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0365","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.prrv.2010.10.005","article-title":"Respiratory manifestations in mucopolysaccharidoses","volume":"12","author":"Muhlebach","year":"2011","journal-title":"Paediatr. Respir. Rev."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0370","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10545-007-0555-5","article-title":"Upper airway obstructive disease in mucopolysaccharidoses: polysomnography, computed tomography and nasal endoscopy findings","volume":"30","author":"Santamaria","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0375","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1034\/j.1600-0455.2002.430108.x","article-title":"Airway changes in children with mucopolysaccharidoses","volume":"43","author":"Shih","year":"2002","journal-title":"Acta Radiol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0380","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF02388760","article-title":"Narrow trachea in mucopolysaccharidoses","volume":"15","author":"Peters","year":"1985","journal-title":"Pediatr. Radiol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0385","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ppul.21246","article-title":"Skeletal dysplasias: evaluation with impulse oscillometry and thoracoabdominal motion analysis","volume":"45","author":"Rodriguez","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0390","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1203\/00006450-198005000-00008","article-title":"Prenatal mucopolysaccharidosis II (Hunter): a pathogenetic study","volume":"14","author":"Wiesmann","year":"1980","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0395","first-page":"122","article-title":"Prenatal pathology in mucopolysaccharidoses: a comparison with postnatal cases","volume":"2","author":"Martin","year":"1983","journal-title":"Clin. Neuropathol."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0400","doi-asserted-by":"crossref","first-page":"60ra89","DOI":"10.1126\/scitranslmed.3001380","article-title":"Replacing the enzyme alpha-l-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I","volume":"2","author":"Dierenfeld","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0405","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1172\/JCI119208","article-title":"Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI","volume":"99","author":"Crawley","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0410","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ymgme.2013.03.005","article-title":"Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice","volume":"109","author":"Baldo","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0415","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1542\/peds.2009-1728","article-title":"Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up","volume":"125","author":"Gabrielli","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2013.11.015_bb0420","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1399-0004.2009.01324.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI from 8weeks of age\u2014a sibling control study","volume":"77","author":"McGill","year":"2010","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0425","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1111\/j.1651-2227.2011.02385.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis II from 3months of age: a 3-year follow-up","volume":"101","author":"Tylki-Szymanska","year":"2012","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0430","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ymgme.2012.12.010","article-title":"Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings","volume":"108","author":"Tajima","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0435","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/GIM.0b013e31817701e6","article-title":"Initial report from the Hunter Outcome Survey","volume":"10","author":"Wraith","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2013.11.015_bb0440","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejmg.2010.07.013","article-title":"First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5years of age: case observations from the Hunter Outcome Survey (HOS)","volume":"53","author":"Alcalde-Martin","year":"2010","journal-title":"Eur. J. Med. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719213004186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719213004186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T06:58:01Z","timestamp":1716274681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719213004186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1096719213004186"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2013.11.015","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early initiation of enzyme replacement therapy for the mucopolysaccharidoses","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2013.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}